ATE257016T1 - Herstellung von virusinaktivierten intravenös injektierbaren globulin aus immunserum - Google Patents

Herstellung von virusinaktivierten intravenös injektierbaren globulin aus immunserum

Info

Publication number
ATE257016T1
ATE257016T1 AT96114439T AT96114439T ATE257016T1 AT E257016 T1 ATE257016 T1 AT E257016T1 AT 96114439 T AT96114439 T AT 96114439T AT 96114439 T AT96114439 T AT 96114439T AT E257016 T1 ATE257016 T1 AT E257016T1
Authority
AT
Austria
Prior art keywords
solution
virus
globulin
inactivated
production
Prior art date
Application number
AT96114439T
Other languages
English (en)
Inventor
William R Alonso
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24120836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE257016(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of ATE257016T1 publication Critical patent/ATE257016T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT96114439T 1995-09-22 1996-09-10 Herstellung von virusinaktivierten intravenös injektierbaren globulin aus immunserum ATE257016T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/532,211 US6686191B1 (en) 1995-09-22 1995-09-22 Preparation of virally inactivated intravenously injectable immune serum globulin

Publications (1)

Publication Number Publication Date
ATE257016T1 true ATE257016T1 (de) 2004-01-15

Family

ID=24120836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96114439T ATE257016T1 (de) 1995-09-22 1996-09-10 Herstellung von virusinaktivierten intravenös injektierbaren globulin aus immunserum

Country Status (10)

Country Link
US (1) US6686191B1 (de)
EP (2) EP1356829A3 (de)
JP (1) JP4036494B2 (de)
AT (1) ATE257016T1 (de)
AU (1) AU709608B2 (de)
CA (1) CA2185859C (de)
DE (1) DE69631229T2 (de)
DK (1) DK0764447T3 (de)
ES (1) ES2213760T3 (de)
PT (1) PT764447E (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0973549A2 (de) * 1997-04-07 2000-01-26 Cangene Corporation Intravenöse immunglobulinzusammensetzungen die ein nichtionisches oberfläche-aktives agens enthält mit verbesserten pharmakokinetischen eigenschaften
AT405608B (de) * 1997-04-08 1999-10-25 Immuno Ag Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
SK139099A3 (en) 1997-04-08 2000-06-12 Baxter Ag Immunotolerant prothrombin complex preparation
WO2001013423A1 (en) * 1999-08-10 2001-02-22 Ibiden Co., Ltd. Semiconductor production device ceramic plate
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
KR100791502B1 (ko) * 2006-09-29 2008-01-03 한스바이오메드 주식회사 바이러스 불활화된 무세포 인체 이식재 생산방법
EP2077118A1 (de) * 2008-01-07 2009-07-08 Gwo Rei Biomedical Technology Corp. Gerinnungsfähiges Konzentrat von Plättchenwachstumsfaktoren und Herstellungsverfahren dafür
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
CN102357259A (zh) 2011-07-28 2012-02-22 王珊珊 一种生物蛋白海绵及其制备方法
JP6182210B2 (ja) 2012-06-29 2017-08-16 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質精製プロセス中のウイルスの不活性化方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396608A (en) * 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4762714A (en) * 1986-04-08 1988-08-09 Miles Laboratories, Inc. Preparation of retrovirus-free immunoglobulins
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
EP0523406B1 (de) * 1991-07-05 1998-12-09 Bayer Corporation Verwendung von Tri-n-Butylphosphat bei niedrigem pH in Lösungen von biologisch aktiven Proteinen für eine verbesserte viruzide Wirkung

Also Published As

Publication number Publication date
AU709608B2 (en) 1999-09-02
ES2213760T3 (es) 2004-09-01
JP4036494B2 (ja) 2008-01-23
CA2185859C (en) 2011-04-19
EP1356829A2 (de) 2003-10-29
EP0764447A2 (de) 1997-03-26
EP0764447B1 (de) 2004-01-02
JPH09124507A (ja) 1997-05-13
AU6569096A (en) 1997-03-27
DK0764447T3 (da) 2004-05-03
EP0764447A3 (de) 1997-07-30
US6686191B1 (en) 2004-02-03
EP1356829A3 (de) 2003-12-17
CA2185859A1 (en) 1997-03-23
DE69631229T2 (de) 2004-12-02
DE69631229D1 (de) 2004-02-05
PT764447E (pt) 2004-04-30

Similar Documents

Publication Publication Date Title
DE69631229D1 (de) Herstellung von virusinaktivierten Intravenös injektierbaren Globulin aus Immunserum
US4764369A (en) Undenatured virus-free biologically active protein derivatives
US4540573A (en) Undenatured virus-free biologically active protein derivatives
US4613501A (en) Inactivation of viruses in labile blood derivatives
US4841023A (en) Inactivation of viruses in labile protein-containing compositions using fatty acids
DE69823931D1 (de) Chromatographieverfahren für Reinigung von IgG mit hoher Ausbeute und Virusinaktivierung
ATE149355T1 (de) Verfahren zur inaktivierung von prionen
DE68903558D1 (de) Verfahren zur inaktivierung von viren.
FI962613A0 (fi) Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi
US4820805A (en) Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
LU91704I2 (fr) Agalsidase alfa et ses dérivées pharmaceutiquementacceptables (REPLAGAL®)
JPS6485929A (en) Sterilization for immnogloblin solution
JPH09124507A5 (de)
GB1488774A (en) Hepatitis b antigen and method of producing it
DK573587A (da) Fremgangsmaade til fremstilling af en faktor viii (ahf)-holdig fraktion
SE7906273L (sv) Sett att framstella en gammaglobulinlosning
EP0523406B1 (de) Verwendung von Tri-n-Butylphosphat bei niedrigem pH in Lösungen von biologisch aktiven Proteinen für eine verbesserte viruzide Wirkung
ATE285255T1 (de) Verfahren zur inaktivierung von viren
AU687153B2 (en) Use of azoles as virucidal agents in solutions of biologically active proteins
EP0571771A3 (en) Method of inactivation of viruses in proteinic preparations
DK0457035T3 (da) Fremgangsmåde til inaktivering af den biologiske aktivitet af DNA
Horowitz et al. Elimination of disease-transmitting enveloped viruses from human blood plasma and mammalian cell culture products: Assurance of virus safety of biological products.
RU94038847A (ru) Способ получения нитерферона
JPS6463600A (en) Method for purifying vitronectin
JPH0430789A (ja) モノクローナル抗体アフィニティカラムによるウイルスの精製法

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0764447

Country of ref document: EP